Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK LIFE SCIENCES vs PARMAX PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK LIFE SCIENCES PARMAX PHARMA GLENMARK LIFE SCIENCES/
PARMAX PHARMA
 
P/E (TTM) x 18.3 -2.6 - View Chart
P/BV x 4.5 1.8 244.9% View Chart
Dividend Yield % 2.7 0.0 -  

Financials

 GLENMARK LIFE SCIENCES   PARMAX PHARMA
EQUITY SHARE DATA
    GLENMARK LIFE SCIENCES
Mar-23
PARMAX PHARMA
Mar-23
GLENMARK LIFE SCIENCES/
PARMAX PHARMA
5-Yr Chart
Click to enlarge
High Rs53458 927.1%   
Low Rs36926 1,400.4%   
Sales per share (Unadj.) Rs176.430.2 584.9%  
Earnings per share (Unadj.) Rs38.1-0.2 -18,688.5%  
Cash flow per share (Unadj.) Rs41.53.5 1,193.7%  
Dividends per share (Unadj.) Rs21.000-  
Avg Dividend yield %4.70-  
Book value per share (Unadj.) Rs174.011.5 1,515.0%  
Shares outstanding (eoy) m122.535.10 2,402.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.61.4 183.9%   
Avg P/E ratio x11.8-205.9 -5.8%  
P/CF ratio (eoy) x10.912.1 90.1%  
Price / Book Value ratio x2.63.7 71.0%  
Dividend payout %55.10-   
Avg Mkt Cap Rs m55,321214 25,838.3%   
No. of employees `000NANA-   
Total wages/salary Rs m1,80228 6,405.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m21,612154 14,053.1%  
Other income Rs m2900 72,392.5%   
Total revenues Rs m21,902154 14,205.3%   
Gross profit Rs m6,42323 28,483.1%  
Depreciation Rs m42119 2,240.2%   
Interest Rs m54 147.8%   
Profit before tax Rs m6,2860 1,366,541.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6162 107,765.3%   
Profit after tax Rs m4,670-1 -449,001.0%  
Gross profit margin %29.714.7 202.7%  
Effective tax rate %25.7326.5 7.9%   
Net profit margin %21.6-0.7 -3,192.9%  
BALANCE SHEET DATA
Current assets Rs m23,68775 31,460.8%   
Current liabilities Rs m10,22871 14,330.3%   
Net working cap to sales %62.32.6 2,441.9%  
Current ratio x2.31.1 219.5%  
Inventory Days Days24 36.4%  
Debtors Days Days136147,800 0.1%  
Net fixed assets Rs m8,51897 8,792.4%   
Share capital Rs m24545 550.6%   
"Free" reserves Rs m21,07014 149,965.8%   
Net worth Rs m21,31559 36,399.0%   
Long term debt Rs m045 0.0%   
Total assets Rs m32,205176 18,284.7%  
Interest coverage x1,150.21.1 102,300.9%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.70.9 76.9%   
Return on assets %14.51.5 963.0%  
Return on equity %21.9-1.8 -1,232.7%  
Return on capital %29.54.0 733.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,6910-   
Fx outflow Rs m5,0010-   
Net fx Rs m4,6890-   
CASH FLOW
From Operations Rs m3,1343 94,115.3%  
From Investments Rs m-1,541-9 16,468.5%  
From Financial Activity Rs m-3,876NA 880,893.2%  
Net Cashflow Rs m-2,283-6 35,291.2%  

Share Holding

Indian Promoters % 82.9 30.8 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.3 0.0 -  
FIIs % 4.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 69.2 24.8%  
Shareholders   185,531 2,002 9,267.3%  
Pledged promoter(s) holding % 9.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK LIFE SCIENCES With:   SUN PHARMA    DIVIS LABORATORIES    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on GLENMARK LIFE SCIENCES vs PARMAX PHARMA

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

GLENMARK LIFE SCIENCES vs PARMAX PHARMA Share Price Performance

Period GLENMARK LIFE SCIENCES PARMAX PHARMA S&P BSE HEALTHCARE
1-Day 0.01% -0.49% 1.18%
1-Month -11.59% -6.87% -0.75%
1-Year 106.25% 3.38% 61.82%
3-Year CAGR 1.19% -7.08% 18.16%
5-Year CAGR 0.71% 10.48% 19.79%

* Compound Annual Growth Rate

Here are more details on the GLENMARK LIFE SCIENCES share price and the PARMAX PHARMA share price.

Moving on to shareholding structures...

The promoters of GLENMARK LIFE SCIENCES hold a 82.9% stake in the company. In case of PARMAX PHARMA the stake stands at 30.8%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of GLENMARK LIFE SCIENCES and the shareholding pattern of PARMAX PHARMA.

Finally, a word on dividends...

In the most recent financial year, GLENMARK LIFE SCIENCES paid a dividend of Rs 21.0 per share. This amounted to a Dividend Payout ratio of 55.1%.

PARMAX PHARMA paid Rs 0.0, and its dividend payout ratio stood at -0.0%.

You may visit here to review the dividend history of GLENMARK LIFE SCIENCES, and the dividend history of PARMAX PHARMA.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.